↓ Skip to main content

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, January 2022
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Published in
Journal of Experimental & Clinical Cancer Research, January 2022
DOI 10.1186/s13046-021-02214-z
Pubmed ID
Authors

Yuanyan Tang, Haisen Yin, Xinying Zhao, Dan Jin, Yan Liang, Tao Xiong, Lu Li, Wen Tang, Jiangzhao Zhang, Min Liu, Zhuojun Yu, Huimin Liu, Sibin Zang, Zhiping Huang

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 20%
Unspecified 4 16%
Student > Master 4 16%
Student > Ph. D. Student 4 16%
Lecturer 2 8%
Other 2 8%
Unknown 4 16%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 20%
Unspecified 4 16%
Medicine and Dentistry 4 16%
Immunology and Microbiology 2 8%
Chemical Engineering 1 4%
Other 4 16%
Unknown 5 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2022.
All research outputs
#12,931,481
of 22,818,766 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#593
of 2,054 outputs
Outputs of similar age
#192,635
of 499,255 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#24
of 79 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,054 research outputs from this source. They receive a mean Attention Score of 4.0. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 499,255 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.